secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001104659-23-020751
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics Q1 loss widens to $18.7M; PDUFA goal date August 29, 2023
------------------------------------------------------------------------------

- Net loss $18.7M ($0.08/share) vs $14.5M ($0.08) in Q1 fiscal 2022.
- Cash and equivalents $52.3M; raised $24M equity and $30M convertible note in Dec 2022.
- FDA PDUFA goal date for ONS-5010 (wet AMD) set for August 29, 2023.
- Pre-launch commercial activities underway; partnership with AmerisourceBergen.
- EMA MAA accepted for ONS-5010; decision expected early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923020751/0001104659-23-020751-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465923020751/tm236701-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-020751

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer